Innophos (IPHS) is one of the few companies that did not make it through 2017 in positive territory. While results did not show much growth, there were significant positives to be taken from the first three quarters of reported results. Innophos met analyst expectations, did not cut guidance at any point throughout the year, and maintained the relatively healthy dividend rate for a corporation (now yielding more than 4%). Further, management did make an interesting acquisition that looks highly compelling given the data available, which will be a key prong within the company's